SOLICITATION NOTICE
D -- PharmaPendium Database Subscription
- Notice Date
- 7/18/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 519130
— Internet Publishing and Broadcasting and Web Search Portals
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, NCATS, National Institute on Drug Abuse, National Center for Advancing Translational Science (NCATS), 6001 Executive Boulevard, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- NIHDA201800353
- Archive Date
- 8/8/2018
- Point of Contact
- Jessica Adams, Phone: 3044438761, Jeffrey Schmidt,
- E-Mail Address
-
jessica.adams@nih.gov, jeffrey.schmidt@nih.gov
(jessica.adams@nih.gov, jeffrey.schmidt@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: PharmaPendium Database Subscription (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is NIHDA201800353 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Station Support Contracts and Simplified Acquisitions Branch (SS/SA) on behalf of the National Center for Advancing Translational Sciences (NCATS) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to Elsevier B.V., Radarweg 29, 1043 NX Amsterdam, The Netherlands for a PharmaPendium database. This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items by soliciting from a single source pursuant to FAR Subpart 13.106-1(b). (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-97, dated January 24, 2018. (iv) The associated NAICS code 519130 and the small business size standard is 500 employees. This requirement is has no set-aside restrictions. (v) The mission of NCATS is to apply the tools of small molecule screening and discovery to the development of chemical probe research tools, for use in the study of protein and cell functions, and biological processes relevant to physiology and disease. The TRND program generates large amounts of high quality data, which need to be evaluated for their value and to guide the TRND projects. The PharmaPendium database provides the critical in vivo human drug toxicity information needed to build and validate predictive models for human toxicity based on the TRND qHTS data. The pre-clinical and clinical safety, pharmacokinetic and metabolizing enzyme and transporter data provided by the PharmaPendium database will be used to assess the TRND qHTS data to build computational models for potential drug induced toxicity in humans. (vi) Physical, Functional, and Performance Specifications 1. PharmaPendium, PK Module for PharmaPendium, PharmaPendium Efficacy Module, Metabolizing Enzymes and Transporters Module 2. Manufactured by Elsevier 3. The function of this database is to provide access to extracted pre-clinical and clinical safety, pharmacokinetic and metabolizing enzyme and transporter data. In addition, this database will provide access to original FDA/EMA drug approval documents and a range of medical and drug development journals that contain vast amounts of crucial pharmacokinetics data that are not available in academic publications. 4. PharmaPendium is a database that provides decision support solution designed to help improve pharmaceutical development. This database provides extracted pre-clinical and clinical safety, pharmacokinetic and metabolizing enzyme and transporter data. PharmaPendium has fully searchable FDA/EMA drug approval documents and access to a whole range of medical and drug development journals that allow the user find relevant information in minutes. PharmaPendium provides access to original FDA/EMA drug approval documents and a whole range of medical and drug development journals along with references from Meyler's Side Effects of Drugs and Mosby's Drug Consult. FDA, EMA and AERS documents contain vast amounts of crucial pharmacokinetics data that never reach academic publications. 5. Elsevier will make the subscribed products accessible to the subscriber and its authorized users from the internet address pharmapendium.com by providing access with a username and password. (vii) Period of Performance: One-year subscription to extend from August 15, 2018 to August 14, 2019. (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: 1. Technical Evaluation Factor: Offeror's technical approach will be evaluated for completeness, feasibility, soundness, and practicality for accomplishing the requirements of the Statement of Work (SOW). 2. Delivery/Period of Performance Evaluation Factor: Contractor's ability to meet or exceed the delivery date/period of performance in the SOW. 3. Cost/Price Evaluation Factor: Offeror(s) cost/price will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. (xiii) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received by 1:00pm, Eastern Standard Time, July 24, 2018 and reference number NIHDA201800353. Responses shall be submitted electronically to Jessica Adams, Contract Specialist at jessica.adams@nih.gov. Fax responses will not be accepted. (xvi) The name and email address of the individual to contact for information regarding the solicitation: Jessica Adams, Contract Specialist at jessica.adams@nih.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/d38677fa891ccb357eb9a786bf765a83)
- Place of Performance
- Address: 9800 Medical Center Drive, Building B, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN04996558-W 20180720/180718230833-d38677fa891ccb357eb9a786bf765a83 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |